Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

NCT05688696 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT05688696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05688696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
April 29, 2023
Completion date
May 30, 2026
Enrollment
186 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus, sle